the aim of this investigation was to improve the storage stability and survival rate of intravesical bcg product, manufactured with an attenuated strain of mycobacterium bovis (pasteur strain 1173p2 of bcg) in the presence of sodium glutamate. formulations with various concentrations of trehalose (a known protectant) were developed as liquid and lyophilized forms. formulations were evaluated by...

introduction bacillus calmette-guérin (bcg) vaccine, a live attenuated mycobacterium bovis strain, is administrated to all newborn infants in endemic regions according to the current world health organization (who) recommendation. case presentation we report a 10-month-boy who was a known case of severe combined immunodeficiency (scid) admitted with multi-focal fusiform painful swelling in his ...

Intravesical Bacillus Calmette-Guérin (BCG) is an established treatment for high-risk superficial bladder cancer [Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guérin in the treatment of superficial bladder tumors.1976. J Urol 2002; 167: 891-893, Lamm DL, van der Meijden APM, Morales A et al. Incidence and treatment of complications of Bacillus Calmette-Guérin intravesical th...

background: bacillus calmette-guérin (bcg) vaccination is recommended for newborn infants worldwide to prevent tuberculosis. however, complications do occur inevitably in a very low rate, among which the most serious is disseminated disease. the disseminated bacillus calmette–guérin disease is a rare disease with high fatality, and can be seen among persons with an underlying immunodeficiency. ...

Background: Bacillus Calmette-Guérin (BCG) vaccination is recommended for newborn infants worldwide to prevent tuberculosis. However, complications do occur inevitably in a very low rate, among which the most serious is disseminated disease. The disseminated bacillus Calmette–Guérin disease is a rare disease with high fatality, and can be seen among persons with an underlying immunodeficiency. ...

Recibido: 08/08/2009 Aceptado: 02/10/2009 Introduction Short title: Bacillus Calmette-Guérin disease after intravesical instillation Two exemplary case reports of respiratory granulomatous infection caused by bacillus of Calmette-Guérin (BCG) in patients who were repeatedly treated with local, intravesical adjuvant BCG therapy for a relapsing transitional bladder carcinoma, are outlined and dis...

Intravesical instillation of Bacillus Calmette-Guérin (BCG) has been shown to be an effective form of immunotherapy for bladder cancer. This case report describes a patient who develops systemic BCG-osis following intravesical BCG instillation and demonstrates the importance of being aware of more severe complications associated with BCG immunotherapy.

Intravesical bacillus Calmette-Guérin (BCG) immunotherapy results in neutrophil recruitment and subsequent secretion of cytokines to eliminate non-muscle invasive bladder cancer cells. However, bladder cancer cells often resist BCG immunotherapy. Thus, understanding the mechanism of action of BCG, and designing appropriate combination therapies might help to overcome BCG resistance and redirect...

Summary Bladder cancer is a heterogeneous disease in molecular, histological and clinical aspects. Treatment should also be considered from different angles - surgery, intravesical chemo- or immunotherapy, radiation therapy lifestyle changes. Intravesical treatment of superficial bladder with Еpirubicin Bacillus Calmette-Guérin (BCG) continuation surgical to reduce eliminate further recurrence.

– Met criteria for one of the following NMIBC treatment groups: • Group 1: Bacillus Calmette–Guérin (BCG)-naïve, treated with transurethral resection of bladder tumor (TURBT) ± intravesical chemotherapy • Group 2: Had current or previous BCG treatment but were refractory or resistant to treatment • Group 3: Were BCG refractory or relapsing and next treatment option would be cystectomy (but were...